UY28218A1 - Compuestos arilvinilazacicloalcano y metodos de preparación y uso de ellos. - Google Patents

Compuestos arilvinilazacicloalcano y metodos de preparación y uso de ellos.

Info

Publication number: UY28218A1
Authority: UY; Uruguay
Prior art keywords: disorders; compounds; disease; central nervous; gastrointestinal
Prior art date: 2003-03-05

Application number

UY28218A

Other languages

English (en)

Spanish (es)

Inventor

Jefrey Daniel Schmitt

Gary Maurice Dull

Arielle Genevois-Barella

Marc Capet

Michel Cheve

Original Assignee

Targacept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-05

Filing date

2004-03-04

Publication date

2005-06-30

2004-03-04 Application filed by Targacept Inc filed Critical Targacept Inc

2005-06-30 Publication of UY28218A1 publication Critical patent/UY28218A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UY28218A 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y metodos de preparación y uso de ellos. UY28218A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/379,868 US7098331B2 (en)	2003-03-05	2003-03-05	Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number	Publication Date
UY28218A1 true UY28218A1 (es)	2005-06-30

Family

ID=32926772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UY28218A UY28218A1 (es)	2003-03-05	2004-03-04	Compuestos arilvinilazacicloalcano y metodos de preparación y uso de ellos.

Country Status (32)

Country	Link
US (8)	US7098331B2 (fr)
EP (3)	EP2085395B1 (fr)
JP (3)	JP4663627B2 (fr)
KR (4)	KR101018083B1 (fr)
CN (3)	CN101255155A (fr)
AR (3)	AR043469A1 (fr)
AT (3)	ATE517893T1 (fr)
AU (3)	AU2004217903B2 (fr)
BR (1)	BRPI0409576A (fr)
CA (1)	CA2516514C (fr)
CL (1)	CL2004000452A1 (fr)
CY (2)	CY1110391T1 (fr)
DE (2)	DE602004031165D1 (fr)
DK (2)	DK1601670T3 (fr)
EA (3)	EA010870B1 (fr)
ES (3)	ES2309507T3 (fr)
GT (1)	GT200400033A (fr)
HK (3)	HK1084949A1 (fr)
IL (3)	IL170155A (fr)
JO (1)	JO2488B1 (fr)
MX (1)	MXPA05009386A (fr)
NO (3)	NO331920B1 (fr)
NZ (1)	NZ541795A (fr)
PA (1)	PA8597201A1 (fr)
PE (1)	PE20040930A1 (fr)
PL (5)	PL216979B1 (fr)
PT (2)	PT1601670E (fr)
SI (2)	SI1601670T1 (fr)
TW (3)	TWI377204B (fr)
UY (1)	UY28218A1 (fr)
WO (1)	WO2004078752A1 (fr)
ZA (1)	ZA200506790B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098331B2 (en) *	2003-03-05	2006-08-29	Targacept, Inc.	Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr)	2006-01-30	2008-04-11	Servier Lab	Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (fr) *	2007-06-15	2008-12-24	Targacept, Inc.	Procédés ou utilisations et compositions pour traiter ou empêcher la douleur neuropathique
US20110098312A1 (en) *	2008-05-12	2011-04-28	Targacept ,Inc	Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) *	2008-12-01	2010-07-01	Targacept Inc	Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
PT3279195T (pt) *	2008-12-01	2020-09-29	Oyster Point Pharma Inc	Síntese e novas formas de sal de (r)-5-((e)-2-pirrolidin- 3-ilvinil)pirimidina
WO2010080757A2 (fr)	2009-01-07	2010-07-15	Astrazeneca Ab	Combinaisons avec un agoniste alpha-4-bêta-2 nicotinique
NZ596734A (en) *	2009-06-17	2014-02-28	Targacept Inc	Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
BR112012013765A2 (pt)	2009-12-07	2016-04-26	Targacept Inc	3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina
WO2011112428A2 (fr) *	2010-03-11	2011-09-15	Targacept, Inc.	Composés arylvinylazacycloalcane pour la constipation
US20110274628A1 (en) *	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) *	2012-09-19	2014-03-20	Salesforce.Com, Inc.	Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) *	2013-03-15	2014-09-18	Yahoo! Inc.	System and method identifying opportunities for advertising entities based on user goal achievement
JP7090551B2 (ja)	2016-04-07	2022-06-24	オイスターポイントファーマインコーポレイテッド	眼状態の治療方法
KR101848601B1 (ko) *	2016-07-27	2018-04-12	송기봉	일회용 위생 티슈
EP3820443A1 (fr)	2018-07-10	2021-05-19	Oyster Point Pharma, Inc.	Combinaisons de modulateurs allostériques positifs et d'agonistes du récepteur nicotinique de l'acétylcholine pour traiter des états oculaires
WO2020014217A1 (fr)	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Méthodes de traitement d'états oculaires
TW202206078A (zh)	2020-04-28	2022-02-16	美商奧伊斯特普安生物製藥公司	局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989000158A1 (fr)	1987-07-02	1989-01-12	Pfizer Inc.	Acides et esters carboxyliques de quinolone de diazabicycloalkyle shunte
US4922901A (en)	1988-09-08	1990-05-08	R. J. Reynolds Tobacco Company	Drug delivery articles utilizing electrical energy
US5187166A (en)	1990-07-31	1993-02-16	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives and their use as antiemetics
IL107184A (en)	1992-10-09	1997-08-14	Abbott Lab	Heterocyclic ether compounds that enhance cognitive function
US5852041A (en)	1993-04-07	1998-12-22	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it)	1994-02-23	1997-07-14	Riace Ets	Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en)	1994-11-23	1996-05-29	Glaxo Inc	Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en)	1995-01-06	1997-02-18	Smith; Carr J.	Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en)	1995-01-06	1997-01-28	Dull; Gary M.	Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en)	1995-04-07	1996-12-17	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en)	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en)	1995-06-07	2006-10-05	Abbott Lab	Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en)	1996-01-06	1997-04-01	Dull; Gary M.	(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de)	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en)	1996-04-23	1997-09-02	Ruecroft; Graham	Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en)	1996-06-06	1997-05-13	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en)	1996-06-06	2002-08-20	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DK1027336T3 (da)	1997-10-27	2005-01-24	Neurosearch As	Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse
AU5326100A (en)	1999-06-07	2000-12-28	Targacept, Inc.	Pharmaceutical compositions and methods for use
EP1212319A2 (fr)	1999-09-14	2002-06-12	Abbott Laboratories	Composes d'ether 3-pyrrolidinyloxy-3'-pyridyle utilises comme regulateurs de la transmission synaptique chimique
JP2003513054A (ja)	1999-11-01	2003-04-08	ターガセプト，インコーポレイテッド	アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) *	2000-08-04	2003-09-23	Targacept, Inc.	Pharmaceutical compositions and methods for use
WO2003008559A2 (fr)	2001-07-19	2003-01-30	Medical College Of Georgia Research Institute	Nouveaux analogues de choline pour la neuroprotection et l'amelioration cognitive dans les troubles neurodegeneratifs
US7098331B2 (en) *	2003-03-05	2006-08-29	Targacept, Inc.	Arylvinylazacycloalkane compounds and methods of preparation and use thereof

2003
- 2003-03-05 US US10/379,868 patent/US7098331B2/en not_active Expired - Lifetime
2004
- 2004-02-10 TW TW098105931A patent/TWI377204B/zh not_active IP Right Cessation
- 2004-02-10 TW TW093103017A patent/TWI339662B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105932A patent/TW200927746A/zh unknown
- 2004-03-02 PE PE2004000228A patent/PE20040930A1/es not_active Application Discontinuation
- 2004-03-04 AU AU2004217903A patent/AU2004217903B2/en not_active Ceased
- 2004-03-04 SI SI200430775T patent/SI1601670T1/sl unknown
- 2004-03-04 ES ES04717398T patent/ES2309507T3/es not_active Expired - Lifetime
- 2004-03-04 PL PL378415A patent/PL216979B1/pl unknown
- 2004-03-04 EP EP09075124A patent/EP2085395B1/fr not_active Expired - Lifetime
- 2004-03-04 NZ NZ541795A patent/NZ541795A/en not_active IP Right Cessation
- 2004-03-04 KR KR1020097002098A patent/KR101018083B1/ko not_active IP Right Cessation
- 2004-03-04 PL PL394604A patent/PL215059B1/pl unknown
- 2004-03-04 AR ARP040100690A patent/AR043469A1/es not_active Application Discontinuation
- 2004-03-04 KR KR1020097002099A patent/KR100953150B1/ko not_active IP Right Cessation
- 2004-03-04 EA EA200501425A patent/EA010870B1/ru active IP Right Revival
- 2004-03-04 PT PT04717398T patent/PT1601670E/pt unknown
- 2004-03-04 EP EP04717398A patent/EP1601670B1/fr not_active Expired - Lifetime
- 2004-03-04 KR KR1020127001576A patent/KR20120014236A/ko not_active Application Discontinuation
- 2004-03-04 GT GT200400033A patent/GT200400033A/es unknown
- 2004-03-04 DE DE602004031165T patent/DE602004031165D1/de not_active Expired - Lifetime
- 2004-03-04 CN CNA2008100917335A patent/CN101255155A/zh active Pending
- 2004-03-04 CN CN2009100048828A patent/CN101550132B/zh not_active Expired - Fee Related
- 2004-03-04 AT AT08075106T patent/ATE517893T1/de not_active IP Right Cessation
- 2004-03-04 BR BRPI0409576-6A patent/BRPI0409576A/pt not_active IP Right Cessation
- 2004-03-04 EA EA200900706A patent/EA019240B1/ru not_active IP Right Cessation
- 2004-03-04 EA EA200801764A patent/EA014714B1/ru not_active IP Right Cessation
- 2004-03-04 PL PL394600A patent/PL394600A1/pl unknown
- 2004-03-04 AT AT09075124T patent/ATE496046T1/de active
- 2004-03-04 ES ES09075124T patent/ES2385941T3/es not_active Expired - Lifetime
- 2004-03-04 EP EP08075106A patent/EP1947100B1/fr not_active Expired - Lifetime
- 2004-03-04 SI SI200431638T patent/SI2085395T1/sl unknown
- 2004-03-04 KR KR1020057016343A patent/KR101185541B1/ko not_active IP Right Cessation
- 2004-03-04 PT PT09075124T patent/PT2085395E/pt unknown
- 2004-03-04 PL PL04717398T patent/PL1601670T3/pl unknown
- 2004-03-04 JP JP2006509059A patent/JP4663627B2/ja not_active Expired - Fee Related
- 2004-03-04 WO PCT/US2004/006530 patent/WO2004078752A1/fr active Application Filing
- 2004-03-04 PA PA20048597201A patent/PA8597201A1/es unknown
- 2004-03-04 DE DE602004013553T patent/DE602004013553D1/de not_active Expired - Lifetime
- 2004-03-04 CA CA2516514A patent/CA2516514C/fr not_active Expired - Lifetime
- 2004-03-04 JO JO200422A patent/JO2488B1/en active
- 2004-03-04 DK DK04717398T patent/DK1601670T3/da active
- 2004-03-04 PL PL09075124T patent/PL2085395T3/pl unknown
- 2004-03-04 CN CNB2004800060242A patent/CN100526308C/zh not_active Expired - Lifetime
- 2004-03-04 AT AT04717398T patent/ATE394394T1/de active
- 2004-03-04 MX MXPA05009386A patent/MXPA05009386A/es active IP Right Grant
- 2004-03-04 UY UY28218A patent/UY28218A1/es not_active Application Discontinuation
- 2004-03-04 ES ES08075106T patent/ES2389106T3/es not_active Expired - Lifetime
- 2004-03-04 DK DK09075124.9T patent/DK2085395T3/da active
- 2004-03-08 CL CL200400452A patent/CL2004000452A1/es unknown
2005
- 2005-08-08 IL IL170155A patent/IL170155A/en active IP Right Grant
- 2005-08-17 US US11/206,243 patent/US20060094732A1/en not_active Abandoned
- 2005-08-24 ZA ZA200506790A patent/ZA200506790B/xx unknown
- 2005-09-05 NO NO20054120A patent/NO331920B1/no not_active IP Right Cessation
2006
- 2006-05-26 HK HK06106130A patent/HK1084949A1/xx not_active IP Right Cessation
2008
- 2008-08-06 CY CY20081100831T patent/CY1110391T1/el unknown
- 2008-08-07 US US12/187,584 patent/US7714001B2/en not_active Expired - Lifetime
- 2008-10-29 HK HK09109159.9A patent/HK1130254A1/xx not_active IP Right Cessation
- 2008-10-29 HK HK08111897.3A patent/HK1116800A1/xx not_active IP Right Cessation
- 2008-12-17 AU AU2008258188A patent/AU2008258188B2/en not_active Ceased
- 2008-12-17 AU AU2008258187A patent/AU2008258187B2/en not_active Ceased
2009
- 2009-01-05 US US12/348,605 patent/US8063068B2/en not_active Expired - Lifetime
- 2009-02-05 AR ARP090100388A patent/AR070569A2/es not_active Application Discontinuation
- 2009-02-05 AR ARP090100389A patent/AR070570A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197890A patent/IL197890A/en active IP Right Grant
- 2009-04-05 IL IL197889A patent/IL197889A/en active IP Right Grant
- 2009-05-14 NO NO20091888A patent/NO332293B1/no not_active IP Right Cessation
- 2009-06-09 NO NO20092231A patent/NO20092231L/no unknown
- 2009-07-31 JP JP2009178896A patent/JP5537084B2/ja not_active Expired - Lifetime
- 2009-07-31 JP JP2009178897A patent/JP5537085B2/ja not_active Expired - Lifetime
2010
- 2010-01-06 US US12/683,106 patent/US8067443B2/en not_active Expired - Fee Related
2011
- 2011-02-24 US US13/033,719 patent/US8633222B2/en not_active Expired - Lifetime
- 2011-04-05 CY CY20111100351T patent/CY1111615T1/el unknown
2013
- 2013-12-17 US US14/108,918 patent/US20140107164A1/en not_active Abandoned
2015
- 2015-02-24 US US14/629,517 patent/US20150164894A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2008258187B2 (en)	2010-08-05
HK1084949A1 (en)	2006-08-11
IL197889A (en)	2013-03-24
AR070569A2 (es)	2010-04-21
CY1110391T1 (el)	2015-04-29
KR101185541B1 (ko)	2012-09-24
ES2389106T3 (es)	2012-10-23
IL170155A (en)	2013-08-29
CL2004000452A1 (es)	2005-05-20
BRPI0409576A (pt)	2006-04-18
US20100267776A1 (en)	2010-10-21
PL378415A1 (pl)	2006-04-03
AR043469A1 (es)	2005-07-27
PE20040930A1 (es)	2005-02-18
KR20060006006A (ko)	2006-01-18
JP2006519868A (ja)	2006-08-31
PL1601670T3 (pl)	2008-10-31
KR20090021228A (ko)	2009-02-27
PT1601670E (pt)	2008-07-11
CN1756754A (zh)	2006-04-05
US8633222B2 (en)	2014-01-21
US20080293778A1 (en)	2008-11-27
US20150164894A1 (en)	2015-06-18
AU2004217903A1 (en)	2004-09-16
NO331920B1 (no)	2012-04-30
AU2008258187A1 (en)	2009-01-15
MXPA05009386A (es)	2005-11-04
US8063068B2 (en)	2011-11-22
NO20091888L (no)	2005-10-03
PL394600A1 (pl)	2011-07-18
EP1601670B1 (fr)	2008-05-07
DE602004013553D1 (de)	2008-06-19
SI1601670T1 (sl)	2008-10-31
TWI339662B (en)	2011-04-01
NO20054120D0 (no)	2005-09-05
EA200900706A1 (ru)	2009-10-30
US7714001B2 (en)	2010-05-11
ES2385941T3 (es)	2012-08-03
EP1947100A1 (fr)	2008-07-23
JP2009292825A (ja)	2009-12-17
AU2008258188A1 (en)	2009-01-15
KR20090021227A (ko)	2009-02-27
US20110152293A1 (en)	2011-06-23
JO2488B1 (en)	2009-10-05
EP2085395A1 (fr)	2009-08-05
DK1601670T3 (da)	2008-08-25
NO20092231L (no)	2005-10-03
HK1116800A1 (en)	2009-01-02
JP2010001296A (ja)	2010-01-07
EA200801764A1 (ru)	2008-12-30
EA014714B1 (ru)	2011-02-28
US20100010042A1 (en)	2010-01-14
NO20054120L (no)	2005-10-03
NO332293B1 (no)	2012-08-20
EA019240B1 (ru)	2014-02-28
CN101550132B (zh)	2012-03-28
ATE517893T1 (de)	2011-08-15
US8067443B2 (en)	2011-11-29
EP2085395B1 (fr)	2011-01-19
HK1130254A1 (en)	2009-12-24
US7098331B2 (en)	2006-08-29
DE602004031165D1 (de)	2011-03-03
CN101550132A (zh)	2009-10-07
IL197890A (en)	2013-11-28
KR20120014236A (ko)	2012-02-16
ZA200506790B (en)	2006-05-31
PL394604A1 (pl)	2011-07-18
AR070570A2 (es)	2010-04-21
PL2085395T3 (pl)	2011-05-31
WO2004078752A1 (fr)	2004-09-16
TWI377204B (en)	2012-11-21
AU2004217903B2 (en)	2010-03-04
PA8597201A1 (es)	2004-09-28
NZ541795A (en)	2008-03-28
PL215059B1 (pl)	2013-10-31
US20040176348A1 (en)	2004-09-09
SI2085395T1 (sl)	2011-05-31
US20060094732A1 (en)	2006-05-04
JP5537084B2 (ja)	2014-07-02
PL216979B1 (pl)	2014-06-30
AU2008258188B2 (en)	2011-02-24
JP4663627B2 (ja)	2011-04-06
TW200505909A (en)	2005-02-16
ATE496046T1 (de)	2011-02-15
GT200400033A (es)	2005-05-29
EP1947100B1 (fr)	2011-07-27
CA2516514C (fr)	2012-02-07
DK2085395T3 (da)	2011-04-18
TW200927745A (en)	2009-07-01
TW200927746A (en)	2009-07-01
CA2516514A1 (fr)	2004-09-16
KR100953150B1 (ko)	2010-04-19
CN100526308C (zh)	2009-08-12
KR101018083B1 (ko)	2011-03-02
EA010870B1 (ru)	2008-12-30
ATE394394T1 (de)	2008-05-15
JP5537085B2 (ja)	2014-07-02
US20140107164A1 (en)	2014-04-17
CN101255155A (zh)	2008-09-03
EP1601670A1 (fr)	2005-12-07
EA200501425A1 (ru)	2006-02-24
PT2085395E (pt)	2011-04-20
ES2309507T3 (es)	2008-12-16
CY1111615T1 (el)	2015-10-07

Legal Events

Date	Code	Title	Description
2013-12-03	104	Application deemed to be withdrawn (no substantive examination fee paid)	Effective date: 20131203

Publication	Publication Date	Title
AR070570A2 (es)	2010-04-21	Compuesto de arilvinilazacicloalcano, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por alfa4beta2 nachr.
CY1122566T1 (el)	2021-01-27	Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
JP2016535786A5 (fr)	2017-03-09
JP2006501240A5 (fr)	2006-06-08
WO2018060732A3 (fr)	2018-06-07	Compositions et méthodes de traitement de troubles épileptiques
UY29796A1 (es)	2007-04-30	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1115484T1 (el)	2017-01-04	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
GT200900294A (es)	2011-08-29	Compuestos amino-heterocíclicos
PL398445A1 (pl)	2012-06-04	Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
BR0309875A (pt)	2007-04-10	métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
ECSP055719A (es)	2005-07-06	Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
UY28376A1 (es)	2005-01-31	Agentes terapéuticos
AR074240A1 (es)	2011-01-05	Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
MX2018003685A (es)	2018-08-15	Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
ECSP088366A (es)	2008-05-30	1,2-diarilimidazoles para uso como moduladores de cb1
PA8657301A1 (es)	2007-01-17	Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento
ECSP088250A (es)	2008-04-28	Derivados de pirazol como agentes terapéuticos
WO2015009731A3 (fr)	2015-03-19	Analogues azacycliques de fty720 à structure contrainte
CL2008003232A1 (es)	2009-11-27	Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
ATE414083T1 (de)	2008-11-15	Ocaperidonsalze und pharmazeutische zusammensetzungen, die diese enthalten
UY28712A1 (es)	2005-08-31	Agentes terapéuticos
ES2969657T3 (es)	2024-05-21	Tratamiento de trastorno de síndrome postraumático
CL2008001136A1 (es)	2009-01-16	Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia.
WO2020106454A3 (fr)	2020-07-23	Compositions analgésiques et anti-accoutumance pour le traitement de la douleur chronique et de la dépendance aux opioïdes
ECSP099644A (es)	2009-10-30	Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico